Skip to main content

Table 3 Prognostic factors for overall survival in HCC patients treated with combination treatment

From: Tumor Hypervascularity and hand-foot-skin reaction predict better outcomes in combination treatment of TACE and Sorafenib for intermediate hepatocellular carcinoma

Characteristics

NO. (N2 = 132)

mOS (month)

Uni-variate HR (95%CI)

p value

Multi-variate HR1a (95%CI)

p value

Multi-variate HR2b (95%CI)

p value

Gender (male/female)

112/20

21.7/15.8

1.095 (0.625–1.917)

0.752

    

Age (< 60/≥60 years)

89/43

21.0/21.7

1.109 (0.720–1.708)

0.640

    

Etiology (HBV/other than HBV)

109/23

21.0/26.3

1.154 (0.688–1.934)

0.587

    

PLT (< 150/≥150 × 10E9/L)

74/58

21.7/21.4

0.970 (0.647–1.457)

0.885

    

Albumin (< 35/≥35 g/L)

20/112

14.3/23.4

1.627 (0.959–2.763)

0.071

    

Bilirubin (≥17/< 17 μmol/L)

51/81

15.9/27.1

1.573 (1.045–2.368)

0.030

1.397 (0.915–2.132)

0.121

1.371 (0.878–2.139)

0.165

AST (≥40/< 40 U/L)

69/63

14.8/32.7

2.008 (1.329–3.034)

0.001

1.859 (1.194–2.894)

0.006

1.854 (1.193–2.883)

0.006

ALT (≥40/< 40 U/L)

56/76

17.1/21.7

0.943 (0.624–1.427)

0.783

    

AFP (≥200/< 200 ng/ml)

67/65

15.7/28.7

1.533 (1.017–2.310)

0.041

1.364 (0.869–2.142)

0.178

1.379 (0.884–2.152)

0.157

Ascites (with/without)

15/117

12.6/21.9

1.975 (1.093–3.569)

0.024

1.136 (0.470–2.764)

0.777

1.149 (0.477–2.769)

0.757

Child-Pugh score (5/6/≥7)

104/20/8

25.1/17.1/12.5

1.606 (1.149–2.244)

0.006

1.895 (1.150–3.123)

0.012

1.907 (1.160–3.137)

0.011

Tumor size (≥7/< 7 cm)

71/61

16.5/26.3

1.457 (0.966–2.199)

0.073

    

No. of HCC nodules (≥2/1)

63/69

14.8/27.1

1.806 (1.200–2.718)

0.005

1.753 (1.134–2.709)

0.012

1.764 (1.138–2.733)

0.011

Sorafenib usage (after/before TACE)

43/89

22.9/21.0

0.932 (0.608–1.430)

0.747

    

Vascularity (hypovascular/hypervascular)

44/88

15.0/25.1

2.003 (1.300–3.085)

0.002

2.103 (1.355–3.266)

0.001

  

HFSR (non-responder/responder)

60/72

15.0/25.1

1.801 (1.201–2.700)

0.004

1.957 (1.281–2.991)

0.002

  

Stratification

 Group A

52

29.1

1

   

1

 

 Group BC

56

16.5

1.729 (1.085–2.758)

0.021

  

1.910 (1.167–3.127)

0.010

 Group D

24

11.9

3.166 (1.802–5.563)

< 0.001

  

4.154 (2.311–7.465)

< 0.001

  1. aMulti-variate HR1, variables of vascularity and 2HFSR60 were included in Cox-regression but not stratification
  2. bMulti-variate HR2, stratification was included after excepting vascularity and 2HFSR
  3. cGroup A: patients with both hypervascularity and HFSR-response; Group BC: patients with either hypervascularity or HFSR-response; Group D patients with hypovascularity and HFSR-nonresponse
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us